Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Gold-Containing Nanoplatforms for Preclinical Spinal Cord Injury: A Scoping Review and Evidence Map.

Created on 19 Nov 2026

Authors

Ding Zhang, Jia Liu, Xingcheng Yi, Fei Yin

Published in

Tissue engineering. Part B, Reviews. Pages 19373368261506877. Nov 18, 2026. Epub Nov 18, 2026.

Abstract

Gold-containing nanoplatforms are increasingly investigated for spinal cord injury (SCI), but their roles within heterogeneous therapeutic systems remain difficult to compare. We conducted a scoping review and evidence map to characterize preclinical SCI studies by platform function, the role of the gold-containing component, and the breadth of experimental validation. Following PRISMA-ScR and JBI guidance, PubMed, Scopus, Web of Science, and Embase were searched from inception to May 26, 2026. Twenty-seven eligible in vivo studies were charted using eight mutually exclusive primary platform categories and nonexclusive biointerface and outcome domains. The most frequent categories were cargo and transcriptional modulation (n = 8), conductive and stimulation-associated interfaces (n = 5), and scaffold and cell support (n = 4). Four recurrent repair problems emerged: local delivery and pathway modulation, lesion bridging and cell retention, bioelectrical support, and secondary-injury microenvironment regulation. Most studies used rats (21/27), thoracic injury models (23/27), and acute intervention contexts (24/27). Motor function and tissue preservation were each evaluated in 24 studies, while sensory, bladder, and respiratory outcomes were less common. Relevant gold-free comparisons were included in 21 studies, including 17 in vivo. Biodistribution, degradation, and clearance or excretion were each assessed in four studies. SYRCLE appraisal identified widespread unclear reporting of key allocation and blinding procedures. These findings suggest that gold is best evaluated as a platform-dependent biointerface rather than a uniform therapeutic agent. More component-resolved controls, longer-term material-fate studies, standardized outcomes, and rigorous reporting are needed to advance reproducible preclinical evidence.

PMID:
43053513
Bibliographic data and abstract were imported from PubMed on 19 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 3
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement